Sign InBreakout Stocks of Week 20 @ HKEX
NASDAQ was up last week (week 19) by 4.51% ending at 26,247.08 points after gaining 1,132.63 points during the week. Our system has detected some possible breakout stocks for the following week and these should be on your watchlist. These are the stocks that are bouncing up with good increase in volume and are likely to do good in short term. One of these stocks are Oshidori International Holdings Limited HKEX:0622. This stock has had a buy signal since Jan 15, 2026 when the price was HK$0.790 and is so far up 160.76% to HK$2.06. Some other companies are on our watchlist to, among these are COSCO SHIPPING Holdings Co., Ltd. HKEX:1919 Csop Hang Seng China Enterprises Index Daily (-2x) Inverse Product HKEX:7588 HKBN Ltd. HKEX:1310 and Ascentage Pharma Group International HKEX:6855 which all got a breakout pattern emerging.
| Date | Company | Price | Week 20 |
|---|---|---|---|
| Oshidori International Holdings Limited | HK$2.06 | HK$2.14 | 3.88% |
| Cosco Shipping Holdings Co., Ltd. | HK$14.72 | HK$14.83 | 0.747% |
| Csop Hang Seng China Enterprises Index Daily (-2x)... | HK$1.45 | HK$1.51 | 4.28% |
| Hkbn Ltd. | HK$7.29 | HK$7.00 | -3.98% |
| Ascentage Pharma Group International | HK$42.64 | HK$39.30 | -7.83% |
The Oshidori International Holdings Limited stock price gained 4.04% on the last trading day (Friday, 8th May 2026), rising from HK$1.98 to HK$2.06. During the last trading day the stock fluctuated 7.18% from a day low at HK$1.95 to a day high of HK$2.09. The price has been going up and down for this period, and there has been a 3% gain for the last 2 weeks. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 16 million more shares were traded than the day before. In total, 24 million shares were bought and sold for approximately HK$49.86 million.
Oshidori International Holdings Limited holds several positive signals and is within a strong rising trend. As the old saying says, "Let the trend be your friend.'". We therefore consider it to be a good choice at these current levels and we are expecting further gains during the next 3 months.
The COSCO SHIPPING Holdings Co., Ltd. stock price fell by -0.271% on the last day (Friday, 8th May 2026) from HK$14.76 to HK$14.72. During the last trading day the stock fluctuated 1.37% from a day low at HK$14.61 to a day high of HK$14.81. The price has been going up and down for this period, and there has been a 1.03% gain for the last 2 weeks. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -8 million shares and in total, 21 million shares were bought and sold for approximately HK$307.57 million.
COSCO SHIPPING Holdings Co., Ltd. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About COSCO SHIPPING Holdings Co., Ltd.:
COSCO SHIPPING Holdings Co., Ltd., an investment holding company, engages in the container shipping, container terminals, and other terminal related businesses in the United States, Europe, the Asia Pacific, Mainland China, and internationally. The company operates through Container Shipping Business and Terminal Business segments. It offers freight forwarding and transportation, vessel chartering, marine, vessel management, manning, and liner agency. The company was formerly known as China COSCO Holdings Company Limited and changed its name to COSCO SHIPPING Holdings Co., Ltd. in November 2016. COSCO SHIPPING Holdings Co., Ltd. was incorporated in 2005 and is based in Shanghai, the People's Republic of China.
Csop Hang Seng China Enterprises Index Daily (-2x) Inverse Product
HKEX:7588The Csop Hang Seng China Enterprises Index ETF price gained 0.555% on the last trading day (Friday, 8th May 2026), rising from HK$1.44 to HK$1.45. During the last trading day the ETF fluctuated 1.66% from a day low at HK$1.44 to a day high of HK$1.47. The price has been going up and down for this period, and there has been a -4.1% loss for the last 2 weeks. Volume fell on the last day by -918 thousand shares and in total, 6 million shares were bought and sold for approximately HK$9.20 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Csop Hang Seng China Enterprises Index holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
The HKBN Ltd. stock price gained 0.83% on the last trading day (Friday, 8th May 2026), rising from HK$7.23 to HK$7.29. It has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the last trading day the stock fluctuated 2.35% from a day low at HK$7.22 to a day high of HK$7.39. The price has fallen in 7 of the last 10 days and is down by -11.1% for this period. Volume has increased on the last day along with the price, which is a positive technical sign, and, in total, 2 million more shares were traded than the day before. In total, 3 million shares were bought and sold for approximately HK$21.49 million.
HKBN Ltd. holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About HKBN Ltd.:
HKBN Ltd., an investment holding company, provides fixed telecommunications network, international telecommunications, and mobile services to residential and enterprise customers primarily in Hong Kong. It offers data connectivity, cloud and data center, managed Wi-Fi, business continuity, system integration, cybersecurity, mobile, and voice and collaboration services; and roaming and digital solutions. The company provides IT and security, data processing/center, telecommunication, administrative support, consulting, enterprise systems, technical and product sale, distribution and logistics, outsourcing, software and programming, broadband, Wi-Fi consultancy and connectivity, and business referrals and consultancy services. It also offers internet, telecommunications, and security devices installation services; holds and invests in properties; sells and markets mirapoint, and email related products; holds licenses; and markets and distributes computer hardware and software, and telecommunication and office automation products, as well as provides related services. The company was founded in 1992 and is headquartered in Kwai Chung, Hong Kong.
The Ascentage Pharma Group International stock price fell by -2.60% on the last day (Friday, 8th May 2026) from HK$43.78 to HK$42.64. During the last trading day the stock fluctuated 2.61% from a day low at HK$42.20 to a day high of HK$43.30. The price has fallen in 8 of the last 10 days and is down by -6.94% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -876 thousand shares and in total, 2 million shares were bought and sold for approximately HK$89.16 million.
Ascentage Pharma Group International holds several negative signals and this should be a sell candidate, but due to the general chance for a turnaround situation it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.
About Ascentage Pharma Group International:
Ascentage Pharma Group International, a clinical-stage biotechnology company, engages in developing therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in the United States and Mainland China. Its primary product HQP1351, a BCR-ABL inhibitor targeting BCR-ABL mutants, including those with the T315I mutation, as well as for patients with tyrosine kinase inhibitor resistant chronic phase chronic myeloid leukemia. It also has APG-2575, an orally administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors, which is under Phase Ib/II clinical study; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interaction for treating solid tumors and hematological malignancies; and APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection. In addition, it is involved in the development of APG-1252, a small molecule drug to restore apoptosis through selective inhibition of the Bcl-2 and Bcl-xL proteins for SCLC, lymphoma, and other solid tumors; APG-2449 for non-small-cell lung carcinoma; APG-5918, an orally available and selective EED inhibitor with a best-in-class potential that is under pre-clinical stage; APG-265, which is in the IND-enabling stage for hematological malignancies and solid tumors; and UBX1967/1325 targeting Bcl family indicated for DME that is under Phase II development. Ascentage Pharma Group International has collaboration relationships with major biotechnology and pharmaceutical companies, and academic institutions, which include Innovent Biologics, Inc.; National Cancer Institute; Pfizer Inc.; and Clover Biopharmaceuticals (Hong Kong) Co., Limited. The company was founded in 2009 and is headquartered in Suzhou, China.
Despite these candidates are looking good from a technical perspective they may not perform as expected. You should always be cautious when trading and base your decisions on more than one source of information. This does not constitute an offer or recommendation to buy or sell securities.
GOLDEN STAR
| Ticker | Change | Signal Date |
|---|---|---|
TPR
$140.47
|
0.306% | Jun 04 |
|
N
NVRI
$19.53
|
1.79% | May 20 |
RUN
$12.83
|
4.91% | May 06 |
GLBE
$31.61
|
1.71% | May 05 |
SAP
$172.39
|
5.53% | May 05 |
